Mesentech has developed a bone-targeting drug-conjugate called MES—1007 that avoids systemic exposure and side effects by specifically delivering drugs to the bone.
It is exceptionally well tolerated and expected to be very safe both in terms of acute and chronic toxicity and side effects.
Latest News
| 09.04.21 | Bob Ward joins Mesentech's Board of Directors |
| 10.03.21 | New article "Design, Synthesis, Pharmacokinetics, and Biodistribution of a Series of Bone-Targeting EP4 Receptor Agonist Prodrugs for Treatment of Osteoporosis and Other Bone Conditions" |
| 26.02.21 | New article "Effects of treatment with a bone-targeted prostaglandin E2 receptor 4 agonist C3 (Mes-1007) in a mouse model of severe osteogenesis imperfecta" |
| More |
Latest News
| 09.04.21 | Bob Ward joins Mesentech's Board of Directors |
| 10.03.21 | New article "Design, Synthesis, Pharmacokinetics, and Biodistribution of a Series of Bone-Targeting EP4 Receptor Agonist Prodrugs for Treatment of Osteoporosis and Other Bone Conditions" |
| 26.02.21 | New article "Effects of treatment with a bone-targeted prostaglandin E2 receptor 4 agonist C3 (Mes-1007) in a mouse model of severe osteogenesis imperfecta" |
| More |
